Neurodevelopmental Outcomes of Very Low Birth Weight Preterm Infants Treated With Poractant Alfa versus Beractant for Respiratory Distress Syndrome

Abstract

Background Some controlled trials have shown significant differences in short-term clinical outcomes between poractant alfa and beractant in infants with respiratory distress syndrome (RDS). There is, however, no study showing the differences in long-term outcomes with these treatments.

Aim To determine and compare the neurodevelopmental outcomes of preterm infants with RDS treated with poractant alfa or beractant at 2 years of age.

Methods This was a prospective, longitudinal, single-center cohort study of infants born at ≤1,500 g and/or ≤32 weeks between 2008 and 2009 who received either poractant alfa (n = 113) or beractant (n = 102) for RDS. Neurological and developmental assessments were performed at a corrected age of 18 to 24 months.

Results About 33 of 113 infants (29.2%) in the poractant alfa group had neurodevelopmental impairment compared with 36 of 102 (35.2%) in the beractant group, and the results did not differ between the groups (p = 0.339). Similarly, no significant difference was found in the percentage of infants with cerebral palsy (11.5 vs. 16.7%, respectively; p = 0.275).

Conclusion Our findings suggest that poractant alfa and beractant are similar in terms of neurodevelopmental outcomes when used for the treatment of RDS in preterm infants.

Keywords

respiratory distress syndrome - poractant alfa - beractant - neurodevelopmental outcome

Note

There are no previous publications or submissions with any overlapping information, including studies and patients.

A statement that the article will not be submitted to any other journal while it is under consideration by American Journal of Perinatology.

Dr. Zeynep Eras had primary responsibility for protocol development, patient screening, enrollment, outcome assessment, preliminary data analysis, and writing the article.

Drs. Evrim Dizdar, Gözde Kanmaz, and Nilufer Guzoglu participated in the development of the protocol and analytical framework for the study and contributed to the writing of the article. Dr. Hatice Tatar Aksoy and child development specialist Gokce Baykal Altunkaya were responsible for patient screening. Dr. Fuat Emre Canpolat and Dr. Ugur Dilmen supervised the design and execution of the study, performed the final data analyses, and contributed to the writing of the article.

A statement that each author listed on the article has seen and approved the submission of this version of the article and takes full responsibility for it. We have no conflict of interest. No financial support was taken for this study.

• References

• 1 Anderson PJ, Doyle LW. Cognitive and educational deficits in children born extremely preterm. Semin Perinatol 2008; 32 (1) 51-58
• 2 Aylward GP. Neurodevelopmental outcomes of infants born prematurely. J Dev Behav Pediatr 2005; 26 (6) 427-440
• 3 Lemons JA, Bauer CR, Oh W, Korones SB, Papille LA, Stoll BJ , et al. Very low birth weight outcomes of the National Institute of Child Health and Human Development Neonatal Research Network, January 1995 through December 1996. NICHD Neonatal Research Network. Pediatrics 2001; 107 (1) E1
• 4 Ramanathan R. Choosing a right surfactant for respiratory distress syndrome treatment. Neonatology 2009; 95 (1) 1-5
• 5 Seger N, Soll R. Animal derived surfactant extract for treatment of respiratory distress syndrome. Cochrane Database Syst Rev 2009; (2) CD007836
• 6 Suresh GK, Soll RF. Lung surfactants for neonatal respiratory distress syndrome: animal-derived or synthetic agents?. Paediatr Drugs 2002; 4 (8) 485-492
• 7 Ramanathan R, Rasmussen MR, Gerstmann DR, Finer N, Sekar K. North American Study Group. A randomized, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants. Am J Perinatol 2004; 21 (3) 109-119
• 8 Malloy CA, Nicoski P, Muraskas JK. A randomized trial comparing beractant and poractant treatment in neonatal respiratory distress syndrome. Acta Paediatr 2005; 94 (6) 779-784
• 9 Gerdes JS, Seiberlich W, Sivieri EM , et al. An open label comparison of calfactant and poractant alfa administration traits and impact on neonatal intensive care unit resources. J Pediatr Pharmacol Ther 2006; 11 (2) 92-100
• 10 Singh N, Hawley KL, Viswanathan K. Efficacy of porcine versus bovine surfactants for preterm newborns with respiratory distress syndrome: systematic review and meta-analysis. Pediatrics 2011; 128 (6) e1588-e1595
• 11 Ramanathan R. Animal-derived surfactants: where are we? The evidence from randomized, controlled clinical trials. J Perinatol 2009; 29 (Suppl. 02) S38-S43
• 12 Barbarello-Andrews L, Marsh W. Pharmacoeconomics of surfactant therapy. J Pediatr Pharmacol Ther 2006; 11 (3) 153-160
• 13 Marsh W, Smeeding J, York JM, Ramanathan R, Sekar K. A cost minimization comparison of two surfactants-beractant and poractant alfa-based upon prospectively designed, comparative clinical trial data. J Pediatr Pharmacol Ther 2004; 9 (2) 117-125
• 14 Dizdar EA, Sari FN, Aydemir C , et al. A randomized, controlled trial of poractant alfa versus beractant in the treatment of preterm infants with respiratory distress syndrome. Am J Perinatol 2012; 29 (2) 95-100
• 15 Bayley N. Bayley Scales of Infant Development II. San Antonio, TX: Psychological Corp; 1993
• 16 Hagberg B, Hagberg G, Olow I, von Wendt L. The changing panorama of cerebral palsy in Sweden. VII. Prevalence and origin in the birth year period 1987-90. Acta Paediatr 1996; 85 (8) 954-960
• 17 Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr 1978; 92 (4) 529-534
• 18 Walsh MC, Kliegman RM. Necrotizing enterocolitis: treatment based on staging criteria. Pediatr Clin North Am 1986; 33 (1) 179-201
• 19 Ramanathan R, Bhatia JJ, Sekar K, Ernst FR. Mortality in preterm infants with respiratory distress syndrome treated with poractant alfa, alfactant or beractant: a retrospective study. J Perinatol 2013; 33 (2) 119-125
• 20 Fujii AM, Patel SM, Allen R, Doros G, Guo CY, Testa S. Poractant alfa and beractant treatment of very premature infants with respiratory distress syndrome. J Perinatol 2010; 30 (10) 665-670
• 21 Sinn JK, Ward MC, Henderson-Smart DJ. Developmental outcome of preterm infants after surfactant therapy: systematic review of randomized controlled trials. J Paediatr Child Health 2002; 38 (6) 597-600
• 22 Auten RL, Merzbach J, Myers G, Goldstein RF, Palumbo D. Neurodevelopmental and health outcomes in term infants treated with surfactant for severe respiratory failure. J Perinatol 2000; 20 (5) 291-294
• 23 Moya F, Sinha S, Gadzinowski J , et al; SELECT and STAR Study Investigators. One-year follow-up of very preterm infants who received lucinactant for prevention of respiratory distress syndrome: results from 2 multicenter randomized, controlled trials. Pediatrics 2007; 119 (6) e1361-e1370
• 24 Robertson B, Curstedt T, Tubman R , et al; Collaborative European Multicentre Study Group. A 2-year follow up of babies enrolled in a European multicentre trial of porcine surfactant replacement for severe neonatal respiratory distress syndrome. Eur J Pediatr 1992; 151 (5) 372-376
• 25 Shankaran S, Johnson Y, Langer JC , et al. Outcome of extremely-low-birth-weight infants at highest risk: gestational age < or = 24 weeks, birth weight < or =750.  g, and 1-minute Apgar < or =3. Am J Obstet Gynecol 2004; 191 (4) 1084-1091
• 26 Moster D, Lie RT, Markestad T. Joint association of Apgar scores and early neonatal symptoms with minor disabilities at school age. Arch Dis Child Fetal Neonatal Ed 2002; 86 (1) F16-F21
• 27 McCrea HJ, Ment LR. The diagnosis, management, and postnatal prevention of intraventricular hemorrhage in the preterm neonate. Clin Perinatol 2008; 35 (4) 777-792 , vii
• 28 O'Shea TM, Allred EN, Kuban KC , et al; ELGAN Study Investigators. Intraventricular hemorrhage and developmental outcomes at 24 months of age in extremely preterm infants. J Child Neurol 2012; 27 (1) 22-29
• 29 Morris BH, Smith KE, Swank PR, Denson SE, Landry SH. Patterns of physical and neurologic development in preterm children. J Perinatol 2002; 22 (1) 31-36
• 30 Vollmer B, Roth S, Baudin J, Stewart AL, Neville BG, Wyatt JS. Predictors of long-term outcome in very preterm infants: gestational age versus neonatal cranial ultrasound. Pediatrics 2003; 112 (5) 1108-1114
• 31 Fanaroff AA, Stoll BJ, Wright LL , et al; NICHD Neonatal Research Network. Trends in neonatal morbidity and mortality for very low birthweight infants. Am J Obstet Gynecol 2007; 196 (2) e1-e8